Who are Free doxorubicin hydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Idamycin Pfs, Idamycin Pfs, Idamycin Pfs, Vincristin , Adriamycin, Dexamethasone = VAD, epidoxorubicine, docetaxel, cyclophosphamide, paclitaxel/Gemcitabine/Liposomal doxorubicin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/free-doxorubicin-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Free doxorubicin hydrochloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Free doxorubicin hydrochloride (Free doxorubicin hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anthracycline antibiotic. Area: Oncology.

phase 2 anthracycline antibiotic DNA, Topoisomerase II Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Free doxorubicin hydrochloride (Free doxorubicin hydrochloride) — Cephalon, Inc.. Doxorubicin hydrochloride intercalates DNA and inhibits topoisomerase II, leading to DNA damage and cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Free doxorubicin hydrochloride TARGET	Free doxorubicin hydrochloride	Cephalon, Inc.	phase 2	anthracycline antibiotic	DNA, Topoisomerase II
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Idamycin Pfs	IDARUBICIN HYDROCHLORIDE		marketed	Anthracycline Topoisomerase Inhibitor	DNA, topoisomerase II	1990-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Vincristin , Adriamycin, Dexamethasone = VAD	Vincristin , Adriamycin, Dexamethasone = VAD	University Hospital, Caen	phase 3	Vinca alkaloid and anthracycline antibiotic	Microtubules and DNA
epidoxorubicine, docetaxel, cyclophosphamide	epidoxorubicine, docetaxel, cyclophosphamide	Sanofi	phase 3	anthracycline antibiotic, taxane, alkylating agent	topoisomerase II, microtubules, DNA
paclitaxel/Gemcitabine/Liposomal doxorubicin	paclitaxel/Gemcitabine/Liposomal doxorubicin	Innovent Biologics (Suzhou) Co. Ltd.	phase 3	Taxane, Nucleoside analog, Anthracycline antibiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anthracycline antibiotic class)

Cephalon, Inc. · 1 drug in this class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Free doxorubicin hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/free-doxorubicin-hydrochloride. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab